Androgen prevents hypogonadal bone loss via inhibition of resorption mediated by mature osteoblasts/osteocytes
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Androgen receptor (AR) is expressed throughout the osteoblast lineage. Two different AR transgenic families (AR2.3-tg and AR3.6-tg mice) demonstrating overlapping and distinct expression profiles were employed to assess the effects of enhanced androgen sensitivity to ameliorate hypogonadal loss. Two different paradigms of steroid replacement following orchidectomy (ORX) were used as either preventative or therapeutic therapy. ORX was performed in male wild-type (WT), AR2.3-tg and AR3.6-tg mice at 5 months with immediate DHT replacement (prevention, higher turnover) or at 3 months with DHT treatment delayed for 2 months (therapeutic, lower turnover), both with treatment for the last 6 weeks. Dual energy x-ray absorptiometry (DXA), microcomputed tomography (μCT), and histomorphometry were performed. In the prevention model, ORX significantly reduced BMD and BMC in all genotypes compared to sham and DHT was effective at prevention of osteopenia. In the therapeutic model, all genotypes became osteopenic compared to sham, but after a prolonged hypogonadal period, delayed DHT treatment provided little benefit. μCT analysis of mid-shaft total bone in all genotypes generally showed reductions after ORX. Delayed DHT was ineffective at restoring bone volume in any genotype whereas immediate treatment prevented loss only in AR transgenic mice. Cortical thickness also decreased with ORX but immediate DHT treatment was effective to increase thickness only in WT mice, likely due to expansion of marrow volume in both AR-tg lines. In metabolically highly active cancellous bone, ORX resulted in lower bone volume/tissue volume (BV/TV) in all genotypes, consistent among 3 sites measured. Again with delayed treatment, there was little effect of DHT to restore BV/TV, but when administered at the time of ORX, DHT completely prevented the decrease in cancellous bone in all genotypes. Improvement in cancellous bone architecture was seen with immediate DHT replacement that was enhanced in AR transgenic lines compared to WT. In contrast, there were only modest changes in all genotypes using the delayed treatment paradigm. With ORX in both paradigms, trabecular number was decreased while spacing increased. Thus, androgen therapy is effective for the prevention of endosteal and cancellous osteopenia primarily through its anti-resorptive properties, but shows little anabolic action as a therapeutic strategy to restore bone. Given the similarity in response to androgen treatment in both AR transgenic lines, overlapping expression profiles suggest that the target cells mediating androgen action in vivo are mature osteoblast/osteocytes. Combined, these results demonstrate that in the adult mouse, androgen treatment can reduce bone resorption but has little overall anabolic activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 1×
“This approach is considered more reliable in mice than determination of serum concentrations by RIA with problematic high variability [27, 28].”
BackgroundFalahati-Nini, A., Riggs, B. L., Atkinson, E. J., O’Fallon, W. M., Eastell, R., & Khosla, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10942 · Cited by 757 · cited 1×
“anti-resorptive responses remains open to debate [11–13].”
Wang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J., Weber, T., Berman, N., Hull, L., & Swerdloff, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032006 · Cited by 656 · cited 2×
“The effectiveness of androgen treatment to increase bone mass and mineral has been evaluated in a variety of clinical trials [8,10].”
BackgroundMechanisms of sex steroid effects on bone
Syed, F., & Khosla, S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.097 · Cited by 380
Differential Effects of Androgens and Estrogens on Bone Turnover in Normal Men
Leder, B. Z., LeBlanc, K. M., Schoenfeld, D. A., Eastell, R., & Finkelstein, J. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021036 · Cited by 283 · cited 1×
“e enhances bone formation) remains open to debate [11, 12].”
BackgroundEffect of testosterone replacement on trabecular architecture in hypogonadal men
Benito, M., Vasilic, B., Wehrli, F. W., Bunker, B., Wald, M., Gomberg, B., Wright, A. C., Zemel, B., Cucchiara, A., & Snyder, P. J. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050606 · Cited by 188 · cited 1×
“Clinical trials that have evaluated the effectiveness of androgen therapy to improve bone mineral density have been disappointing, with only the most hypogonadal patients benefiting [9, 10].”
BackgroundRichman, C., Kutilek, S., Miyakoshi, N., Srivastava, A. K., Beamer, W. G., Donahue, L. R., Rosen, C. J., Wergedal, J. E., Baylink, D. J., & Mohan, S. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.386 · Cited by 104 · cited 1×
“We performed ORX in sexually-mature mice at 3 or 5 months of age, as the rapid pre-pubertal and pubertal growth phase in mice has slowed by 2 months of age [30].”
MethodGunness, M., & Orwoll, E. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101117 · Cited by 86 · cited 1×
“DHT was administered with constant release pellets over 6 weeks, which has previously been shown to be sufficient time for treatment after gonadectomy to observe changes in bone histomorphometry [31] and in cancellous bone mass [32].”
MethodWiren, K. M., Semirale, A. A., Zhang, X.-W., Woo, A., Tommasini, S. M., Price, C., Schaffler, M. B., & Jepsen, K. J. (2008) · Bone · doi:10.1016/j.bone.2008.04.026 · Cited by 65 · cited 6×
“5 months of age is consistent with decreased endocortical bone formation observed during development [15, 16].”
BackgroundMethodSelf-citationSemirale, A. A., Zhang, X., & Wiren, K. M. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23098 · Cited by 42 · cited 1×
“Notably, the novel aspects of the consequences of unique AR overexpression in stem cells and immature osteoblasts is a body composition phenotype with reduced fat and increased muscle mass [19, 20], not observed in AR2.”
BackgroundSelf-citationWiren, K. M., Hashimoto, J. G., & Zhang, X.-W. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23288 · Cited by 5
Self-citation
Cited by
De Souza, M. J., Nattiv, A., Joy, E., Misra, M., Williams, N. I., Mallinson, R. J., Gibbs, J. C., Olmsted, M., Goolsby, M., Matheson, G., et al. (2014) · British Journal of Sports Medicine · doi:10.1136/bjsports-2013-093218 · Cited by 661
Golds, G., Houdek, D., & Arnason, T. (2017) · International Journal of Endocrinology · doi:10.1155/2017/4602129 · Cited by 150
Carvalho, A. L., Brooks, D. J., Barlow, D., Langlais, A. L., Morrill, B., Houseknecht, K. L., Bouxsein, M. L., Lian, J. B., King, T., Farina, N. H., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4690 · Cited by 7
Metadata
- Authors
- Wiren, K. M., Zhang, X.-W., Olson, D. A., Turner, R. T., & Iwaniec, U. T.
- Venue
- Bone
- Publisher
- Elsevier BV
- Published
- 2012-11
- Volume
- 51
- Issue
- 5
- Pages
- 835-846
- ISSN
- 1873-2763 (ISSN-L)
- 8756-3282
- OpenAlex
- W2017406883
- Cited by
- 46
- References
- 11
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.